Exchange: NASDAQ·Updated 05:39 PM EDT
CRVS logo

CRVSCorvus Pharmaceuticals Inc

$13.05
$0.10
(0.77%)
Today
Closed $13.05
$0.00
(0.00%)
After Hours
EarningsAug 6
Mkt Cap$1.09B
Vol1.31M
News
all
press releases
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Key PointsDavid Scott Moore acquired 21,700 common shares for a transaction value of approximately $250,000 on June 11, 2026...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) have been given an average rating of "Moderate Buy" by the eight research firms that are presently covering the stock...
MarketBeat
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 8.3% - Here's Why
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 8.3% - What's Next...
MarketBeat
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by Wall Street Zen to "Hold" Rating
Wall Street Zen raised shares of Corvus Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Down 10.2% - Here's Why
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Down 10.2% - What's Next...
MarketBeat
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Up 9.5% - What's Next?
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading 9.5% Higher - Here's What Happened...
MarketBeat
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded at The Goldman Sachs Group
The Goldman Sachs Group raised shares of Corvus Pharmaceuticals to a "strong-buy" rating in a research note on Friday...
MarketBeat
News Placeholder
CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% Upside
Goldman Sachs initiated coverage of Corvus with a ‘Buy’ rating and $40 price target, according to The Fly.
Stocktwits
News Placeholder
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - Here's What Happened
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up - What's Next...
MarketBeat
News Placeholder
This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says
Corvus Pharmaceuticals is developing an oral drug for a common skin condition that could push its shares a lot higher, according to Goldman Sachs...
CNBC: Top News
<
1
2
...
>

Advertisement|Remove ads.